依达拉奉联合疏血通注射液治疗急性脑梗死大鼠的疗效与安全性评价

发布时间：2018-06-27 20:11

本文选题：急性脑梗死 + MCAO模型　；参考：《中华中医药杂志》2017年09期

【摘要】：目的:评价依达拉奉联合疏血通注射液治疗急性脑梗死大鼠的疗效和安全性。方法:将SD大鼠随机分为:假手术组、模型组、依达拉奉组、疏血通组、依达拉奉联合疏血通组,采用线栓法复制大鼠左侧大脑中动脉脑缺血(middle cerebral artery occlusion,MCAO)模型,除假手术组外,每组按不同时间点(1、3、5、7d)分为4个亚组,术后各组腹腔注射相应药物,1次/d,连续给药1、3、5、7d,模型组、假手术组分别予以等体积0.9%氯化钠溶液,观察比较各组大鼠神经功能缺损评分、脑组织梗死体积、脑组织含水量、脑组织形态学改变及白细胞计数(WBC)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、肌酐(Cr)、尿素氮(BUN)、磷酸肌酸激酶(CK)、乳酸脱氢酶(LDH)、活化部分凝血活酶时间(APTT)等变化。结果:与假手术组比较,其余各组神经功能缺损评分、脑组织含水量、脑梗死体积均显著增高(P0.05,P0.01);与模型组比较,各用药组的神经功能缺损评分、脑组织含水量、脑梗死体积和安全性评价指标(WBC、AST、APTT)均有不同程度降低(P0.05,P0.01);与依达拉奉组、疏血通组比较,联合用药组的神经功能缺损评分、脑组织含水量、脑梗死体积减少更明显(P0.05,P0.01),安全性指标差异无统计学意义。结论:依达拉奉联合疏血通在改善大鼠神经功能缺损症状、减少脑梗死体积、减轻脑水肿3个方面均优于依达拉奉组、疏血通组,且不良反应发生率低,安全性较好。
[Abstract]:Objective: to evaluate the efficacy and safety of Edaravone combined with Shuxuetong injection in the treatment of acute cerebral infarction rats. Methods: SD rats were randomly divided into three groups: sham operation group, model group, Edaravone group, Shuxuetong group, Edaravone combined with Shuxuetong group. The left middle cerebral artery (MCAO) was induced by (middle cerebral artery occlusion. Each group was divided into 4 subgroups according to different time points (1: 3, 5? 5? 7 days). Each group received intraperitoneal injection of the corresponding drug once a day for 7 days. The model group and sham operation group were given 0.9% sodium chloride solution of the same volume, respectively. The neurological impairment scores of each group were observed and compared. The changes of infarct volume, water content of brain tissue, morphology of brain tissue, WBC, alt, AST, Cr, bun, CK, LDH, APTT, etc. Results: compared with the sham operation group, the scores of nerve function defect, the water content of brain tissue and the volume of cerebral infarction were significantly increased in the other groups (P0.05, P0.01), and compared with the model group, the neurological function defect score and the water content of brain tissue in the other groups were significantly higher than those in the model group. Compared with Edaravone group and Shuxuetong group, compared with Edaravone group and Shuxuetong group, the neurological deficit score and water content of brain tissue in combined treatment group were lower than those in Edaravone group and Shuxuetong group. Cerebral infarction volume decreased more significantly (P 0.05 P 0.01), there was no significant difference in safety index. Conclusion: Edaravone combined with Shuxuetong is superior to Edaravone group and Shuxuetong group in improving neurological deficit symptoms, reducing cerebral infarction volume and alleviating cerebral edema.
【作者单位】：湖南中医药大学第一附属医院;湖南中医药大学;
【基金】：湖南省科技厅重点项目(No.2014SK2007)~~
【分类号】：R743.3

【相似文献】